Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Slutsky is a top 100 analyst with an average return of 43.2% and a 51.21% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Spyre Therapeutics, Abivax SA Sponsored ADR, and Palvella Therapeutics.
ArriVent BioPharma, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $44.33.
Based on ArriVent BioPharma, Inc.’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $43.32 million. In comparison, last year the company had a GAAP net loss of $64.39 million
